dobutamine has been researched along with pyrazines in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hosokawa, T; Kojima, M; Mori, T; Yabuuchi, Y; Yamashita, S | 1 |
| Hashimoto, K; Mori, T; Yabuuchi, Y; Yamashita, S | 1 |
| Bax, JJ; Cornel, JH; Fioretti, PM; Krenning, EP; Poldermans, D; Rambaldi, R; Valkema, R; van Lingen, A; Visser, FC | 1 |
| Brouwer, EM; Saris, WH; Schiffelers, SL; van Baak, MA | 1 |
| Hesselink, MK; Hoeks, J; Hul, GB; Saris, WH; Schrauwen, P; van Baak, MA; Vidal, H | 1 |
| Cas, LD; Cotter, G; Gheorghiade, M; Metra, M; Sabbah, HN; Teerlink, JR; Zacà, V | 1 |
2 review(s) available for dobutamine and pyrazines
| Article | Year |
|---|---|
FDG SPECT in the assessment of myocardial viability. Comparison with dobutamine echo.
Topics: Cardiotonic Agents; Deoxyglucose; Dobutamine; Echocardiography; Exercise Test; Fluorodeoxyglucose F18; Glucose; Humans; Hypolipidemic Agents; Myocardial Contraction; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Predictive Value of Tests; Pyrazines; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 1997 |
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.
Topics: Acute Disease; Cardiotonic Agents; Digoxin; Dobutamine; Etiocholanolone; Exercise Test; Heart Failure; Hemodynamics; Hospitals, Group Practice; Humans; Hydrazones; Prognosis; Pyrazines; Pyridazines; Quinolines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Treatment Outcome; Urea; Vasodilator Agents | 2009 |
1 trial(s) available for dobutamine and pyrazines
| Article | Year |
|---|---|
Effect of beta1- and beta2-adrenergic stimulation on energy expenditure, substrate oxidation, and UCP3 expression in humans.
Topics: Adult; Albuterol; Carrier Proteins; Dobutamine; Dose-Response Relationship, Drug; Energy Metabolism; Fats; Fatty Acids, Nonesterified; Glucose; Humans; Ion Channels; Male; Mitochondrial Proteins; Muscle, Skeletal; Oxygen Consumption; Pyrazines; Receptors, Adrenergic, beta; Thigh; Uncoupling Protein 3 | 2003 |
3 other study(ies) available for dobutamine and pyrazines
| Article | Year |
|---|---|
In vitro and in vivo studies of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, in various animals.
Topics: Aminopyridines; Amrinone; Animals; Blood Pressure; Cardiotonic Agents; Cardiovascular System; Cats; Dobutamine; Dogs; Female; Guinea Pigs; Heart Rate; In Vitro Techniques; Male; Myocardial Contraction; Phentolamine; Pindolol; Pyrazines; Quinolines; Rabbits; Rats; Sodium-Potassium-Exchanging ATPase; Theophylline | 1984 |
Positive inotropic effect of 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212) in the dog with experimentally-induced right-sided heart failure.
Topics: Administration, Oral; Aminopyridines; Amrinone; Animals; Blood Pressure; Cardiotonic Agents; Dobutamine; Dogs; Dose-Response Relationship, Drug; Heart Failure; Heart Rate; Injections, Intravenous; Male; Myocardial Contraction; Pyrazines; Quinolines | 1984 |
Inhibition of lipolysis reduces beta1-adrenoceptor-mediated thermogenesis in man.
Topics: Adrenergic beta-Agonists; Adult; Blood Chemical Analysis; Blood Pressure; Body Temperature Regulation; Carbohydrate Metabolism; Dobutamine; Energy Metabolism; Fatty Acids, Nonesterified; Glycerol; Heart Rate; Humans; Hypolipidemic Agents; Lipid Metabolism; Lipolysis; Male; Pyrazines; Receptors, Adrenergic, beta-1; Respiration | 1998 |